Skip to content Skip to footer
Subscribe Now
Abbott
NEWS

Abbott Receives the European CE Mark for Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Shots: Abbott has received European CE Mark approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with peripheral artery disease (PAD) below the knee (BTK) Esprit was evaluated in the LIFE-BTK trial against balloon angioplasty in pts (n >260) with PAD BTK, which showed sustained efficacy & ability to open vessels…
August 27, 2025

Read more

Abbott
NEWS

Abbott Reports the Approval for its Denosumab Biosimilar in Thailand 

Shots:  Abbott has secured regulatory approval for its denosumab biosimilar in Thailand, increasing access to advanced treatments for osteoporosis and cancer-related bone loss  Denosumab is a mAb that works by targeting RANKL, which regulates bone metabolism & osteoclast formation   Abbott will offer denosumab as part of its strategy to expand access to quality medicines in…
August 26, 2025

Read more

VIEWPOINTS

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 

Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 2025

Read more

VIEWPOINTS_Matthew G. Fishler_2023
VIEWPOINTS

Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System

Shots:  Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots   Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms   Equipped with i2i™ communication technology, AVIER DR eliminates…
November 20, 2023

Read more

VIEWPOINTS_Grant Kim_2023
VIEWPOINTS

Grant Kim Shares His Views from the Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Achieving All Three Primary Endpoints

Shots: Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…
September 19, 2023

Read more

VIEWPOINTS_Dr. Christopher Piorkowski_2023
VIEWPOINTS

Dr. Christopher Piorkowski Shares His Views on the US FDA Approval of TactiFlex Ablation Catheter to Treat Abnormal Heart Rhythm

Shots: Christopher started by highlighting the working of the TactiFlex Ablation Catheter and how it can be used for the treatment of patients with Atrial Fibrillation He also talked about the study design and the key findings from the TactiFlex AF IDE trial. He later gave a comparative view of the TactiFlex catheter vs. conventional…
September 11, 2023

Read more

Load more